Humacyte (HUMA) Long-Term Debt Issuances (2020 - 2025)
Humacyte (HUMA) posted quarterly Long-Term Debt Issuances of $88.0 million for Q4 2025, up 345.34% quarter-over-quarter from $19.8 million in Q3 2024.
Humacyte (HUMA) Long-Term Debt Issuances (2020 - 2025) Analysis & Trends
Humacyte (HUMA) has reported Long-Term Debt Issuances for 5 consecutive years, with $88.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $88.0 million; the TTM figure through Dec 2025 stood at $88.0 million (up 340.0% YoY), while the FY2025 annual figure was $88.0 million, up 340.0% from the prior year.
- Long-Term Debt Issuances climbed to $88.0 million in Q4 2025 per HUMA's latest filing, from $19.8 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $88.0 million in Q4 2025 and bottomed at -$19.8 million in Q2 2024.
- Historically, Long-Term Debt Issuances has averaged $25.3 million across 4 years, with a median of $19.8 million in 2024.
- Annual changes were most pronounced in 2021 — Long-Term Debt Issuances surged 10411.27% — and 2024, when it slumped 150.18%.
- Humacyte's Long-Term Debt Issuances stood at $10.0 million in 2021, then soared by 293.77% to $39.4 million in 2023, then plunged by 49.82% to $19.8 million in 2024, then jumped by 345.34% to $88.0 million in 2025.
- Business Quant data shows HUMA's Long-Term Debt Issuances at $88.0 million in Q4 2025, $19.8 million in Q3 2024, and -$19.8 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Humacyte | 150.77 Mn | 150.77 Mn | -825,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 88.00 Mn |
| Dec 31, 2025 | 88.00 Mn |
| Sep 30, 2024 | 19.76 Mn |
| Sep 30, 2024 | 19.76 Mn |
| Jun 30, 2024 | -19.76 Mn |
| Jun 30, 2024 | -19.76 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Jun 30, 2023 | 39.38 Mn |
| Jun 30, 2023 | 39.38 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Mar 31, 2021 | 19.66 Mn |
| Mar 31, 2021 | 19.66 Mn |
| Dec 31, 2020 | 95,136.00 |
| Dec 31, 2020 | 95,136.00 |
| Sep 30, 2020 | 89,076.00 |
| Sep 30, 2020 | 89,076.00 |